Redhill Biophrma ADR (RDHL) Stock Price, Quote & News

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 541 3131

Fax: 972 3 541 3144

Website: www.redhillbio.com

Address:

21 Ha’arba’a Street, Tel Aviv-Yafo, Israel

Patrick2343 Jul. 28 at 3:57 PM

$RDHL Redhill Biopharma Annual Employee Count 2025 13 2024 35 2023 53 2022 113 2021 201 2020 182 Down to 13 employees but still have to dilute nonstop. Send out worthless fluff PR's because there is no way you could be running any sort of trial with 13 employees. What a scam.

0 · Reply

Patrick2343 Jul. 28 at 2:15 PM

$RDHL Anothe wortless fluff pr to try and drive it up so they can dilute. These fluff pr's no longer work people are onto their scam.

0 · Reply

JuggernautRaider Jul. 27 at 11:56 AM

$NEXR $PRZO $DFNS $RDHL Three of these four companies are definitely scams, hurting Americans and our Department of Defense / War… and the SEC does NOTHING. 😤 😡 🇺🇸

0 · Reply

JuggernautRaider Jul. 21 at 4:47 PM

$PPBT who cares. I want them to sell CM24 to my American friends. Gil Efron was a scam artist worse than the $SUNE or $NEXR or $RDHL CEOs… but CM24 could save lives. I intend to do something about it @Duediligence20 instead of complaining Tony ⚾️ 🇺🇸 💥 🏈 ⚾️ 🎇 🏀 🏉 ⚾️

1 · Reply

JuggernautRaider Jul. 21 at 10:12 AM

$PRZO an Isrseli scam is an Israel scam and they are ROBBING US BLINDZ 🇺🇸 $NEXR $PPBT $RDHL Our Do Nothing politiicans keep dicking us over… 🍆 and we do nothing 😑 America may be screwed with these politics 🗳️

1 · Reply

JuggernautRaider Jul. 20 at 4:45 PM

$RDHL another israeli scam 🇮🇱 😩 AVOID 🛑

0 · Reply

Patrick2343 Jul. 9 at 2:42 PM

$RDHL its amazing this company still exists its nothing but a dilute and pay themselves scam. They have never advanced any drugs its all bs studies done on rats.

0 · Reply

JuggernautRaider Jul. 8 at 2:20 PM

$TNXP is not some Israeli scam like $PPBT or $RDHL or $DFNS my friend. Seth has no where to run or hide 🏃‍♂️ 🕳️ 🤨

0 · Reply

JuggernautRaider Jul. 7 at 3:23 PM

Tell me about it brother. And don’t grt me started about the real scams killing us American capitalists, like those Israeli monsters 😤 $NEXR $PPBT $RDHL $DFNS all SCAMS!! 🇺🇸

0 · Reply

Patrick2343 Jul. 6 at 5:37 PM

$RDHL let me guess wants to dilute more

0 · Reply

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Jul 2, 2026, 8:00 AM EDT - 4 weeks ago

RedHill Biopharma Registration statement: Registration filing

Jul 1, 2026, 8:00 AM EDT - 4 weeks ago

RedHill Biopharma Slides: Corporate presentation

Jun 22, 2026, 4:10 PM EDT - 6 weeks ago

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

CPIX

2026-06-18T12:09:53.000Z - 6 weeks ago

RedHill Biopharma announces $19.4M private placement

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

RedHill Biopharma Announces Up To $19.4 Million Private Placement

CPIX

2026-06-16T12:00:00.000Z - 7 weeks ago

RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside

GILD JAZZ RCKT

2026-06-10T14:00:00.000Z - 7 weeks ago

RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst

GILD

2026-06-09T11:06:29.000Z - 2 months ago

RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation

Jun 9, 2026, 7:00 AM EDT - 2 months ago

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

CPIX

2026-06-08T11:12:24.000Z - 2 months ago

RedHill Biopharma launches enforcement of $11M judgment against Kukbo

Jun 8, 2026, 7:00 AM EDT - 2 months ago

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

CPIX

Jun 2, 2026, 8:00 AM EDT - 2 months ago

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

CPIX

May 26, 2026, 11:23 AM EDT - 2 months ago

Bessor Announces Entering Option for the Redhill Property

May 17, 2026, 7:00 AM EDT - 2 months ago

RedHill Biopharma Slides: Corporate presentation

2026-04-30T11:52:17.000Z - 3 months ago

RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease

Apr 30, 2026, 7:00 AM EDT - 3 months ago

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

CPIX

Apr 27, 2026, 8:00 AM EDT - 3 months ago

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

CPIX

2026-04-22T12:40:23.000Z - 3 months ago

RedHill Biopharma announces presentation of preclinical data on opaganib at AACR

Apr 22, 2026, 8:00 AM EDT - 3 months ago

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

CPIX

Apr 6, 2026, 4:22 PM EDT - 4 months ago

RedHill Biopharma Slides: Corporate presentation

2026-02-25T12:17:19.000Z - 5 months ago

RedHill Biopharma announces full sales and operational launch of Talicia

CPIX

Feb 25, 2026, 7:00 AM EST - 5 months ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

CPIX

2026-01-05T12:05:42.000Z - 7 months ago

RedHill Biopharma announces development progress for RHB-102

Jan 5, 2026, 7:00 AM EST - 7 months ago

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

2025-12-15T12:10:59.000Z - 8 months ago

RedHill Biopharma announces in vivo results on opaganib, venetoclax

Dec 15, 2025, 7:00 AM EST - 8 months ago

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

2025-12-01T12:11:10.000Z - 8 months ago

RedHill Biopharma regains compliance with Nasdaq equity requirement

Dec 1, 2025, 7:00 AM EST - 8 months ago

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

2025-11-04T17:05:24.000Z - 9 months ago

RedHill says $10.5M New York Supreme Court judgment now final for enforcement

2025-11-04T14:35:55.000Z - 9 months ago

RedHill Biopharma announces $10.5M New York Supreme Court judgment win

Nov 4, 2025, 9:30 AM EST - 9 months ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Oct 22, 2025, 4:50 PM EDT - 10 months ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

2025-10-20T13:05:16.000Z - 10 months ago

RedHill Biopharma signs strategic partnership with Cumberland

CPIX

Oct 20, 2025, 9:05 AM EDT - 10 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

Oct 6, 2025, 8:00 AM EDT - 10 months ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

2025-09-29T11:10:10.000Z - 11 months ago

RedHill Biopharma wins New York Supreme Court appeal

2025-09-29T11:05:11.000Z - 11 months ago

RedHill Biopharma wins New York Supreme Court appeal

Sep 29, 2025, 7:00 AM EDT - 11 months ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 5, 2025, 7:00 AM EDT - 11 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

2025-08-20T13:10:09.000Z - 1 year ago

RedHill awarded $1.82M in legal costs and expenses in action against Kukbo

Aug 20, 2025, 9:00 AM EDT - 1 year ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

2025-08-18T13:05:11.000Z - 1 year ago

RedHill Biopharma receives Talicia licensing payments totaling $1.1M

Aug 18, 2025, 9:00 AM EDT - 1 year ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

2025-07-21T13:12:17.000Z - 1 year ago

RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease

Jul 21, 2025, 9:00 AM EDT - 1 year ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 1, 2025, 12:00 PM EDT - 1 year ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

May 13, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 2, 2025, 7:00 AM EDT - 1 year ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

Apr 28, 2025, 7:03 AM EDT - 1 year ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 17, 2025, 4:01 PM EDT - 1 year ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 16, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 10, 2025, 7:48 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Mar 18, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 12, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 25, 2025, 7:00 AM EST - 1 year ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 4, 2025, 7:00 AM EST - 1 year ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Jan 21, 2025, 7:00 AM EST - 1 year ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 1, 2024, 7:00 AM EDT - 2 years ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Sep 30, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 9, 2024, 7:00 AM EDT - 2 years ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 5, 2024, 7:00 AM EDT - 2 years ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 3, 2024, 7:00 AM EDT - 2 years ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Aug 29, 2024, 7:00 AM EDT - 2 years ago

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 26, 2024, 7:00 AM EDT - 2 years ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Talicia® Launched in the United Arab Emirates

Aug 19, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Patrick2343 Jul. 28 at 3:57 PM

0 · Reply

Patrick2343 Jul. 28 at 2:15 PM

$RDHL Anothe wortless fluff pr to try and drive it up so they can dilute. These fluff pr's no longer work people are onto their scam.

0 · Reply

JuggernautRaider Jul. 27 at 11:56 AM

$NEXR $PRZO $DFNS $RDHL Three of these four companies are definitely scams, hurting Americans and our Department of Defense / War… and the SEC does NOTHING. 😤 😡 🇺🇸

0 · Reply

JuggernautRaider Jul. 21 at 4:47 PM

1 · Reply

JuggernautRaider Jul. 21 at 10:12 AM

1 · Reply

JuggernautRaider Jul. 20 at 4:45 PM

$RDHL another israeli scam 🇮🇱 😩 AVOID 🛑

0 · Reply

Patrick2343 Jul. 9 at 2:42 PM

$RDHL its amazing this company still exists its nothing but a dilute and pay themselves scam. They have never advanced any drugs its all bs studies done on rats.

0 · Reply

JuggernautRaider Jul. 8 at 2:20 PM

$TNXP is not some Israeli scam like $PPBT or $RDHL or $DFNS my friend. Seth has no where to run or hide 🏃‍♂️ 🕳️ 🤨

0 · Reply

JuggernautRaider Jul. 7 at 3:23 PM

Tell me about it brother. And don’t grt me started about the real scams killing us American capitalists, like those Israeli monsters 😤 $NEXR $PPBT $RDHL $DFNS all SCAMS!! 🇺🇸

0 · Reply

Patrick2343 Jul. 6 at 5:37 PM

$RDHL let me guess wants to dilute more

0 · Reply

focafoca99 Jul. 1 at 11:40 AM

$RDHL rescheduled its annual general meeting to Aug 6, 2026, and updated proxy materials with new board and auditor proposals.

1 · Reply

Patrick2343 Jun. 30 at 7:27 PM

$RDHL if they have any revenue at all coming in they would not need to dilute nonstop.

0 · Reply

JuggernautRaider Jun. 30 at 1:10 PM

$RDHL israeli scam. Short this shit and make some money today 💴

0 · Reply

focafoca99 Jun. 29 at 11:15 AM

$RDHL raised its ATM offering limit with a prospectus supplement to increase ADS capacity.

0 · Reply

cryptoish Jun. 26 at 3:19 PM

$RDHL fuck this shit .. scammers

0 · Reply

focafoca99 Jun. 25 at 11:16 AM

$RDHL scheduled its annual shareholders meeting for July 28, 2026.

0 · Reply

JuggernautRaider Jun. 24 at 1:42 PM

$RDHL Israeli scam just like Netanyahoo 😡 avoid

0 · Reply

I_Hate_Stock_Twits Jun. 23 at 8:44 PM

$RDHL so the now have approximately 30M of ADS (taking into account warrants), so the future market cap of the company at 0.7 $ / share is in the low 20 million range. Bites; stock is not a low MC company any more. Company will likely be shorted back to $0.70 before it will be allowed to be diluted again (point is that the company is being enticed to be rewarded for a puff PR).

1 · Reply

JuggernautRaider Jun. 23 at 1:27 PM

$RDHL israeli scsm just like $NVCR $NEXR and others 🤫

1 · Reply

MrTicker Jun. 22 at 8:43 PM

$RDHL RedHill Biopharma Closes Private Placement MT NEWSWIRES 3:42 PM ET 6/22/2026 04:42 PM EDT, 06/22/2026 (MT Newswires) -- RedHill Biopharma(RDHL) said late Monday it has closed its private placement, raising some $6 million upfront with up to about $13.4 million of potential proceeds upon the exercise in full of its warrants. The placement includes nearly 8.6 million American depositary shares, series A-1 warrants, and series A-2 warrants at $0.70 per ADS and accompanying warrants, the firm said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

0 · Reply

MrTicker Jun. 22 at 8:10 PM

$RDHL RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PR NEWSWIRE 3:10 PM ET 6/22/2026

2 · Reply

focafoca99 Jun. 22 at 11:20 AM

$RDHL announces its annual general meeting set for July 28, 2026.

0 · Reply

Market Cap	3.95M
Revenue (ttm)	290,000.00
Net Income (ttm)	-430,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-148.28%
Debt to Equity Ratio	0.00

Volume	18,413
Avg Vol	237,364
Day's Range	N/A - N/A
Shares Out	6.08M
Stochastic %K	20%
Beta	4.98
Analysts	Strong Buy
Price Target	$40.00